The trial will study the efficacy of IDCT — an allogenic, injectable disc cell therapy — in treating mild to moderate degenerative disc disease.
An independent data safety monitoring company gave the all-clear after it completed a final mid-trial safety review following the treatment of the first six subjects in the high dose study group.
DiscGenics plans to treat a total of 60 subjects in the clinical study.
More articles on biologics:
Dr. Erich Anderer discusses the impact of a single payer system in spine
Differences in Canadian, U.S. spine care: Q&A with Dr. Stephanie de Vere
Dr. Thomas Loftus: How a single-payer system would harm spine practice in the US
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
